B-cell receptor specific for pneumococcal capsular polysaccharide epitopes (BCR)

B-cell receptors (BCRs) specific for pneumococcal capsular polysaccharide (CPS) epitopes are membrane-bound immunoglobulins on B lymphocytes that recognize the complex carbohydrate structures of Streptococcus pneumoniae (Pollard et al., 2009). These receptors initiate B-cell activation and differentiation upon binding to specific polysaccharide antigens, which are typically T-cell independent type 2 (TI-2) antigens (Snapper, 2018). Because pure polysaccharides do not easily induce memory, conjugate vaccines link these antigens to carrier proteins to recruit T-cell help, enhancing the BCR-mediated response and inducing long-term immunity (Kelly et al., 2005). Targeting these receptors via vaccination is the primary strategy for preventing invasive pneumococcal diseases like pneumonia and meningitis (CDC, 2023). The vast diversity of over 100 pneumococcal serotypes requires multivalent vaccines to provide broad protection (Geno et al., 2015). Successful engagement of these receptors leads to the production of opsonizing antibodies that facilitate the clearance of the bacteria by phagocytes (AlonsoDeVelasco et al., 1995). Monitoring the response of these receptors is essential for evaluating vaccine efficacy and the development of next-generation immunotherapies (FDA, 2021).

Other names

Pneumococcal polysaccharide-specific B-cell receptorAnti-CPS BCRSurface immunoglobulin specific for Streptococcus pneumoniae capsular polysaccharides

The binding of pneumococcal capsular polysaccharide antigens to the B-cell receptor triggers a signaling cascade involving kinases like Lyn and Syk, leading to B-cell proliferation and the production of serotype-specific antibodies (Pollard et al., 2009). In the case of conjugate vaccines, the B-cell receptor internalizes the polysaccharide-protein complex, allowing for T-cell involvement and isotype switching to high-affinity IgG (Kelly et al., 2005).